Silence Therapeutics (SLN) Capital Expenditures (2024 - 2025)

Silence Therapeutics (SLN) posted Capital Expenditures of $69000.0 for Q3 2025, up 483.33% sequentially from -$18000.0 in Q2 2025, and up 110.73% YoY from $32743.2 in Q3 2024.

Silence Therapeutics (SLN) Capital Expenditures (2024 - 2025) Analysis & Trends

Silence Therapeutics has reported Capital Expenditures for 2 years, with the latest figure at $69000.0 in Q3 2025.

  • Quarterly Capital Expenditures rose 110.73% year-over-year to $69000.0 in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $51000.0 (down 76.28% YoY) and the FY2025 annual result came in at $55000.0, down 73.93% from the prior year.
  • Capital Expenditures rose to $69000.0 in Q3 2025 per SLN's latest filing, from -$18000.0 in the prior quarter.
  • Over five years, Capital Expenditures peaked at $769000.0 in Q4 2024 and troughed at -$643000.0 in Q3 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 112.20 Mn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 240.20 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - 2.29 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 25.02 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 572,662.23
7 Royalty Pharma 33.72 Bn 35.84 Bn - 251.02 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 34.68 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 6.26 Mn
10 Silence Therapeutics 648.22 Mn 576.12 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 -257,000.00
Dec 31, 2025 -257,000.00
Sep 30, 2025 69,000.00
Sep 30, 2025 69,000.00
Jun 30, 2025 -18,000.00
Jun 30, 2025 -18,000.00
Mar 31, 2025 4,000.00
Mar 31, 2025 4,000.00
Dec 31, 2024 769,000.00
Dec 31, 2024 769,000.00
Sep 30, 2024 -643,000.00
Sep 30, 2024 -643,000.00
Jun 30, 2024 85,000.00
Jun 30, 2024 85,000.00